◆ 会议时间：2020年2月6-8日
◆ 会议地点：捷克共和国 布拉格
◆ 主办单位：欧洲肝脏研究协会(EASL)

◆ 会议简介：
会议将讨论作为执业医师和/或科学家应了解的肝细胞癌(HCC)和胆管癌(CCA)的最新研究进展。领域国际医学会议网。

——未经本站允许，禁止复制、转载、镜像本站任何内容。

◆ 关键日期：
Abstract submission closes：26 November 2019
Early registration deadline ：9 December 2019
Full fee registration ：10 December 2019 – 8 February 2020
The Liver Cancer Summit： 6-8 February 2020

◆ 会议主题：
- Preclinical research on the mechanisms of malignant transformation of hepatic cells and of cell-to-cell interactions
- Basic and translational research on the biology, genetics, and immunology of HCC and CCA
- New developments in HCC and CCA management, including new targeted agents and recent data and implications for immunotherapy of HCC and CCA
- Personalized medicine
- The new challenge of microbiota and liver cancer
- Novel biomarker concepts in HCC and CCA
- Discussions on clinical trials between academia, pharma and regulatory agencies

◆ 注册费：
REGISTRATION FEES ARE EXCLUSIVE OF 21% VAT.

EASL members
Early fee: EUR 300.00
Up to & incl. 09 December 2019 (23:59 UTC+1)

Full fee: EUR 450.00
From 10 December 2019 to 08 February 2020

Non EASL members
Early fee: EUR 450.00
Up to & incl. 09 December 2019 (23:59 UTC+1)

Full fee: EUR 550.00
From 10 December 2019 November 2019 to 08 February 2020

◆ 欢迎信：

Welcome Message for the Liver Cancer Summit 2020

Welcome to the 2020 Liver Cancer Summit, the home of liver cancer research, which will address the latest developments in hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) that you as a practicing physician and/or scientist should know. In our welcome message we have to let you know that this year, for the first time, this successful meeting will have a new title “Liver Cancer Summit” instead of the well-known “HCC Summit” to reflect the growing preclinical and clinical data and rapidly changing treatment landscape of CCA in addition to HCC. This year the Liver Cancer Summit will be held in Prague/Czech Republic.

The biology of liver cancer remained obscure for many years. However, over the last period of time, an intense preclinical research shed new light on the molecular mechanisms involved in the malignant transformation of hepatic cells (mainly hepatocytes and cholangiocytes) and in their interaction with the stroma and immune system. In addition, new risk factors for liver cancer has been described and need to be considered. Moreover, clinical trials have identified novel perspectives and strategies for the accurate diagnosis, management and treatment for HCC and CCA. While these developments offer many new opportunities for your patients, it is becoming increasingly difficult to keep track and timely implement these changes into daily clinical practice and research projects. This multidisciplinary meeting is organized to provide an update on the current knowledge and future directions on the study of HCC and CCA, and its significance under a clinical point of view. Also, the aim of this multidisciplinary summit is to bring physicians and scientists together and promote the exchange of clinical knowledge, the discussion of controversial issues and the establishment of collaborations.

The program will feature state of the art lectures on updated key aspects of HCC and CCA by renowned experts and rising stars covering a broad spectrum of topics, such as:
· Preclinical research on the mechanisms of malignant transformation of hepatic cells and of cell-to-cell interactions
· Basic and translational research on the biology, genetics, and immunology of HCC and CCA
· New developments in HCC and CCA management, including new targeted agents and recent data and implications for immunotherapy of HCC and CCA
· Personalized medicine
· The new challenge of microbiota and liver cancer
· Novel biomarker concepts in HCC and CCA
· Discussions on clinical trials between academia, pharma and regulatory agencies

Panel discussion with experts will open a discussion on the new directions and avenues for research and clinical practice. Special emphasis will be placed on involving young clinicians and scientists, who will have the opportunity to gain a compact overview of the field and build new networks by easily getting in touch with advanced scientists and key opinion leaders. The meeting offers many opportunities to share your research results (selected abstracts will be presented as oral presentation, poster blast, poster) and clinical ideas and to get new inspiration for your own career.

We kindly invite you to come to Prague and get involved into the future of Liver Cancer.
Sincerely,
The Scientific Organizing Committee
Jesus Banales, Valerie Paradis and Lorenza Rimassa